Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center.
Liver venous deprivation (LVD)
hepatectomy
liver failure
portal embolization
Journal
Hepatobiliary surgery and nutrition
ISSN: 2304-3881
Titre abrégé: Hepatobiliary Surg Nutr
Pays: China (Republic : 1949- )
ID NLM: 101600750
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
7
9
2019
pubmed:
7
9
2019
medline:
7
9
2019
Statut:
ppublish
Résumé
Preoperative portal vein embolization (PVE) is currently the standard technique used routinely to increase the size of the future remnant liver (FRL) before major hepatectomies. The degree of hypertrophy (DH) is approximatively 10% and requires on average six weeks. ALPPS is faster and achieves a good DH but with a higher morbidity and mortality. One method recently proposed to increase the FRL is liver venous deprivation (LVD), but its clinical and operative impact is still unknown. The aim of this study is to compare intra- and postoperative morbidity/mortality and the histological evaluation of the liver parenchyma between PVE and LVD in patients undergoing anatomic right hepatectomy. Fifty-three consecutive patients undergoing PVE and LVD before a major hepatectomy were retrospectively analysed between 2015 and 2017. In order to reduce the bias, only potential standard right hepatectomies were selected. Surgical resections and the radiologic procedures were performed by the same Institution. Intra-operative parameters (transfusions, perfusions, bleeding, operative time), postoperative complications (Clavien-Dindo and ISGLS criteria), and histological findings were compared. To induce FRL growth 16 patients underwent PVE and 13 LVD. One patient of the PVE group was not resected due to peritoneal metastases. Surgery was performed for hepatocellular carcinoma (PVE =9, LVD =3), metastases (PVE =5, LVD =10), or others diseases (PVE =2, LVD =0). Per- and post-operative morbidity/mortality rates after PVE and LVD procedures were null. No differences between the two groups were found in terms of intraoperative bleeding (median: 550 Despite the limitations of our study, to our knowledge this is the first report to compare the two techniques LVD is a promising and safe procedure to induce a fast FRL hypertrophy, showing similar mortality/morbidity rates during and after surgery compared to PVE.
Sections du résumé
BACKGROUND
BACKGROUND
Preoperative portal vein embolization (PVE) is currently the standard technique used routinely to increase the size of the future remnant liver (FRL) before major hepatectomies. The degree of hypertrophy (DH) is approximatively 10% and requires on average six weeks. ALPPS is faster and achieves a good DH but with a higher morbidity and mortality. One method recently proposed to increase the FRL is liver venous deprivation (LVD), but its clinical and operative impact is still unknown. The aim of this study is to compare intra- and postoperative morbidity/mortality and the histological evaluation of the liver parenchyma between PVE and LVD in patients undergoing anatomic right hepatectomy.
METHODS
METHODS
Fifty-three consecutive patients undergoing PVE and LVD before a major hepatectomy were retrospectively analysed between 2015 and 2017. In order to reduce the bias, only potential standard right hepatectomies were selected. Surgical resections and the radiologic procedures were performed by the same Institution. Intra-operative parameters (transfusions, perfusions, bleeding, operative time), postoperative complications (Clavien-Dindo and ISGLS criteria), and histological findings were compared.
RESULTS
RESULTS
To induce FRL growth 16 patients underwent PVE and 13 LVD. One patient of the PVE group was not resected due to peritoneal metastases. Surgery was performed for hepatocellular carcinoma (PVE =9, LVD =3), metastases (PVE =5, LVD =10), or others diseases (PVE =2, LVD =0). Per- and post-operative morbidity/mortality rates after PVE and LVD procedures were null. No differences between the two groups were found in terms of intraoperative bleeding (median: 550
CONCLUSIONS
CONCLUSIONS
Despite the limitations of our study, to our knowledge this is the first report to compare the two techniques LVD is a promising and safe procedure to induce a fast FRL hypertrophy, showing similar mortality/morbidity rates during and after surgery compared to PVE.
Identifiants
pubmed: 31489302
doi: 10.21037/hbsn.2019.07.06
pii: hbsn-08-04-329
pmc: PMC6700017
doi:
Types de publication
Journal Article
Langues
eng
Pagination
329-337Commentaires et corrections
Type : CommentIn
Type : CommentIn
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Br J Surg. 2007 Nov;94(11):1386-94
pubmed: 17583900
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Ann Surg. 2009 Apr;249(4):608-16
pubmed: 19300228
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):410-2
pubmed: 19890603
Surgery. 2010 Jun;147(6):805-10
pubmed: 20494211
Surgery. 2011 May;149(5):713-24
pubmed: 21236455
Surgery. 2011 May;149(5):680-8
pubmed: 21316725
HPB (Oxford). 2011 Aug;13(8):528-35
pubmed: 21762295
Ann Surg. 2012 Mar;255(3):405-14
pubmed: 22330038
Dig Surg. 2012;29(1):79-85
pubmed: 22441624
Cardiovasc Intervent Radiol. 2013 Feb;36(1):25-34
pubmed: 22806245
Surgery. 1990 May;107(5):521-7
pubmed: 2333592
World J Surg Oncol. 2013 Jun 11;11:134
pubmed: 23758777
World J Surg. 2014 Jun;38(6):1510-9
pubmed: 24748319
Surgery. 2015 Apr;157(4):690-8
pubmed: 25704417
World J Surg. 2015 Dec;39(12):2990-8
pubmed: 26304608
Eur Radiol. 2016 Dec;26(12):4259-4267
pubmed: 27090112
Br J Surg. 2016 Dec;103(13):1768-1782
pubmed: 27633328
Eur Radiol. 2017 Aug;27(8):3343-3352
pubmed: 28101681
Ann Surg Oncol. 2017 Jun;24(6):1557-1568
pubmed: 28188502
World J Surg. 2017 Jul;41(7):1848-1856
pubmed: 28417185
HPB (Oxford). 2017 Aug;19(8):682-687
pubmed: 28465090
Surgery. 2017 Oct;162(4):775-783
pubmed: 28732555
Surg Oncol. 2017 Sep;26(3):257-267
pubmed: 28807245
World J Surg Oncol. 2017 Dec 19;15(1):227
pubmed: 29258518
Visc Med. 2017 Dec;33(6):419-425
pubmed: 29344515
Visc Med. 2017 Dec;33(6):426-433
pubmed: 29344516
Surgery. 2018 Aug;164(2):227-232
pubmed: 29753461
HPB (Oxford). 2018 Dec;20(12):1109-1118
pubmed: 30057123
Cardiovasc Intervent Radiol. 2018 Dec;41(12):1885-1891
pubmed: 30238334
Surgery. 2019 Mar;165(3):525-533
pubmed: 30482517